Lexington, MA, United States of America

Chuenlei Parng

USPTO Granted Patents = 4 

Average Co-Inventor Count = 3.6

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2010-2023

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Chuenlei Parng: Innovator in Antibody and Screening Technologies

Introduction

Chuenlei Parng is a notable inventor based in Lexington, MA (US). He has made significant contributions to the fields of biotechnology and pharmacology, holding a total of 4 patents. His work primarily focuses on the development of antibodies and innovative screening methods.

Latest Patents

Among his latest patents, one notable invention is the "Anti-E-selectin antibodies, compositions and methods of use." This invention provides antibodies and antigen-binding fragments that specifically bind to E-selectin, along with methods for their use. Another significant patent is related to "Methods of screening agents for activity using teleosts." This invention outlines methods for screening agents for angiogenesis activity, toxic activity, and effects on cell death in teleosts. It also includes high-throughput methods for screening agents in multi-well plates.

Career Highlights

Chuenlei Parng has worked with prominent companies in the pharmaceutical industry, including Phylonix Pharmaceuticals, Inc. and Pfizer Corporation. His experience in these organizations has allowed him to contribute to various innovative projects and advancements in drug development.

Collaborations

Throughout his career, Chuenlei has collaborated with esteemed colleagues such as Patricia McGrath and George N Serbedzija. These collaborations have further enriched his research and development efforts.

Conclusion

Chuenlei Parng is a distinguished inventor whose work in antibody development and screening technologies has made a significant impact in the field. His innovative patents and collaborations highlight his commitment to advancing biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…